Actively Recruiting
Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study
Led by Mayo Clinic · Updated on 2026-03-03
6150
Participants Needed
1
Research Sites
470 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study explores the potential value of a new blood test approach for early detection of cancer.
CONDITIONS
Official Title
Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient has a biopsy confirmed diagnosis of target histology for tissue samples
- Tissue samples from different primary cancers are allowed if from distinct target organs
- Tumors from patients with genetic cancer predisposition may be included if stratified
- Controls do not have the diagnosis of target histology for tissue samples
- For blood samples, cases have biopsy confirmed or clear radiographic diagnosis of target cancer
- Controls for blood samples have no diagnosis of target cancer
- For urine samples, cases have biopsy confirmed or clear radiographic diagnosis of target cancer
- Controls for urine samples have no diagnosis of target cancer
- Participants must be 18 years or older
You will not qualify if you...
- Patients with any transplants prior to tissue collection are excluded
- Patients who received chemotherapy drugs within 5 years prior to tissue collection are excluded
- Cases with radiation to target lesion before tissue collection are excluded
- Patients with multi-centric/multi-focal breast cancer with differing genetic profiles are excluded
- Patients with bilateral breast cancer or ductal carcinoma in situ are excluded
- Patients with known cancer outside target cancer within 5 years prior to blood or urine collection are excluded
- Patients with chemotherapy in 5 years prior to blood or urine collection are excluded
- Patients with prior radiation therapy to target lesion before blood or urine collection are excluded
- Patients with biopsy to target organ/lesion within 3 days before blood or urine collection are excluded
- Patients who had intervention to completely remove target pathology are excluded
- Patients with recurrent target pathology are excluded
- Patients with chronic indwelling urinary catheter or recent urinary tract infection are excluded for urine samples
- Patients without primary bladder, ureter, or urethral cancer but with history of these cancers are excluded for urine samples
- Patients with multi-centric/multi-focal breast cancer with differing genetic profiles are excluded
- Patients with bilateral breast cancer or ductal carcinoma in situ are excluded
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here